Cochrane · systematic review · CD008538
Sargramostim (GM‐CSF) for induction of remission in Crohn's disease
Roth, L, MacDonald, JK, McDonald, JWD, et al. · Cochrane Database of Systematic Reviews · 2011 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 2 · 40%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
GM‐CSF versus placebo for induction of remission in Crohn's disease
Population: patients with induction of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Induction of clinical remission (CDAI < or = 150) GM‐CSF vs placebo | RR 1.67 [0.8, 3.5] | 3 studies · 537 participants | Low Downgraded: imprecision, inconsistency |
Induction of 100‐point clinical response GM‐CSF vs placebo | RR 1.71 [0.98, 2.97] | 3 studies · 537 participants | Low Downgraded: imprecision, inconsistency |
Induction of 70‐point clinical response GM‐CSF vs placebo | RR 1.23 [0.83, 1.82] | 1 study · 124 participants | Low Downgraded: imprecision |
Adverse events GM‐CSF vs placebo | RR 1.06 [0.99, 1.15] | 2 studies · 251 participants | Moderate Downgraded: imprecision |
Serious adverse events GM‐CSF vs placebo | RR 2.17 [0.82, 5.7] | 2 studies · 251 participants | Moderate Downgraded: imprecision |